YU82202A - Derivati tropana i njihova primena - Google Patents

Derivati tropana i njihova primena

Info

Publication number
YU82202A
YU82202A YUP82202A YU82202A YU 82202 A YU82202 A YU 82202A YU P82202 A YUP82202 A YU P82202A YU 82202 A YU82202 A YU 82202A
Authority
YU
Yugoslavia
Prior art keywords
fluorine atoms
therapy
optionally substituted
derivatives useful
tropane derivatives
Prior art date
Application number
Other languages
English (en)
Inventor
Manoussos Perros
David Anthony Price
Blanda Luzia Christa Stammen
Anthony Wood
Original Assignee
Pfizer Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0014046A external-priority patent/GB0014046D0/en
Priority claimed from GB0015835A external-priority patent/GB0015835D0/en
Application filed by Pfizer Inc. filed Critical Pfizer Inc.
Priority to MEP-693/08A priority Critical patent/ME00555A/xx
Priority to RSP-2009/0438A priority patent/RS51436B/en
Publication of YU82202A publication Critical patent/YU82202A/sh
Publication of RS50904B publication Critical patent/RS50904B/sr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates

Abstract

Ovaj pronalazak se odnosi na jedinjenja formule (I): gde je R1, C3-6cikloalkil koji je po potrebi supstituisan jednim ili više atoma fluora, ili C1-6 alkil koji je po potrebi supstituisan jednim ili više atoma fluora, ili C3-6 cikloalkilmetil koji je po potrebi u prstenu supstituisan jednim ili više atoma fluora; i R2 je fenil koji je po potrebi supstituisan jednim ili više atoma fluora, na njegove farmaceutski prihvatljie soli i solvate i na postupke dobijanja intermedijera koji se dalje koriste za dobijanje preparata, kao i upotrebu ovih jedinjenja.[The present invention provides compounds of the formula (I): wherein R1 is C3-6 cycloalkyl optionally substituted by one or more fluorine atoms, or C1-6 alkyl optionally substituted by one or more fluorine atoms, or C3-6 cycloalkylmethyl optionally ring-substituted by one or more fluorine atoms; and R2 is phenyl optionally substituted by one or more fluorine atoms, to pharmaceutically acceptable salts and solvates thereof, and to processes for the preparation of, intermediates used in the preparation of, compositions containing and the uses of, such compounds.
YUP82202 2000-05-26 2001-05-09 Derivati tropana i njihova primena RS50904B (sr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
MEP-693/08A ME00555A (en) 2000-05-26 2001-05-09 Tryasolyl tropane derivatives as ccr5 modulators
RSP-2009/0438A RS51436B (en) 2000-05-26 2001-05-09 DERIVATIVES TRIAZOLIL TROPANA KAO MODULATORS CCR5

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0014046A GB0014046D0 (en) 2000-05-26 2000-05-26 Compounds useful in therapy
GB0015835A GB0015835D0 (en) 2000-06-27 2000-06-27 Compounds useful in therapy

Publications (2)

Publication Number Publication Date
YU82202A true YU82202A (sh) 2005-11-28
RS50904B RS50904B (sr) 2010-08-31

Family

ID=26244452

Country Status (51)

Country Link
EP (3) EP1526134B1 (sh)
JP (2) JP3693957B2 (sh)
KR (2) KR100523501B1 (sh)
CN (2) CN100355753C (sh)
AP (1) AP1965A (sh)
AR (2) AR028622A1 (sh)
AT (2) ATE260914T1 (sh)
AU (2) AU2001252482B2 (sh)
BG (1) BG65966B1 (sh)
BR (1) BRPI0110955B8 (sh)
CA (1) CA2408909C (sh)
CR (1) CR10145A (sh)
CU (1) CU23288B7 (sh)
CY (2) CY2008006I2 (sh)
CZ (1) CZ299102B6 (sh)
DE (3) DE122008000011I1 (sh)
DK (2) DK1526134T3 (sh)
DZ (1) DZ3464A1 (sh)
EA (2) EA007580B1 (sh)
EE (1) EE05110B1 (sh)
EG (1) EG24137A (sh)
ES (3) ES2215129T3 (sh)
FR (1) FR08C0007I2 (sh)
GE (1) GEP20063799B (sh)
HK (3) HK1054927A1 (sh)
HR (1) HRP20020938B1 (sh)
HU (1) HU225810B1 (sh)
IL (2) IL152531A0 (sh)
IS (1) IS2511B (sh)
LT (1) LTC1284974I2 (sh)
LU (1) LU91417I2 (sh)
MA (1) MA26902A1 (sh)
ME (1) ME00555A (sh)
MX (1) MXPA02011631A (sh)
MY (3) MY131019A (sh)
NL (1) NL300338I2 (sh)
NO (3) NO327892B1 (sh)
NZ (1) NZ521477A (sh)
OA (1) OA12264A (sh)
PA (1) PA8517101A1 (sh)
PE (1) PE20011371A1 (sh)
PL (1) PL200551B1 (sh)
PT (2) PT1526134E (sh)
RS (2) RS51436B (sh)
SI (2) SI1526134T1 (sh)
SK (1) SK286129B6 (sh)
TN (1) TNSN01077A1 (sh)
TR (1) TR200400541T4 (sh)
TW (1) TWI230160B (sh)
UY (1) UY26727A1 (sh)
WO (1) WO2001090106A2 (sh)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2215129T3 (es) * 2000-05-26 2004-10-01 Pfizer Inc. Derivados de triazolil tropano como modulares de ccr5.
RU2003137766A (ru) * 2001-06-12 2005-05-20 Ск Корпорейшн (Kr) Новые фенилалкильные аналоги диаминов и амидов
SE0200919D0 (sv) * 2002-03-25 2002-03-25 Astrazeneca Ab Chemical compounds
US6855724B2 (en) 2002-04-08 2005-02-15 Agouron Pharmaceuticals, Inc. Tropane derivatives useful in therapy
ATE328882T1 (de) * 2002-04-08 2006-06-15 Pfizer Tropanderivative als ccr5-modulatoren
GB0208071D0 (en) * 2002-04-08 2002-05-22 Pfizer Ltd Tropane derivatives useful in therapy
MXPA04011577A (es) * 2002-05-23 2005-03-07 Pfizer Metodo para la identificacion de un ligando, por el cual se mide el tiempo de residencia del receptor.
AU2003297048A1 (en) 2002-12-13 2004-07-09 Smithkline Beecham Corporation Cyclohexyl compounds as ccr5 antagonists
DE10336274A1 (de) * 2003-08-07 2005-03-10 Honeywell Specialty Chemicals Verfahren zur Herstellung von geminalen Difluoralkanen
AU2004268847A1 (en) 2003-08-29 2005-03-10 Ranbaxy Laboratories Limited Inhibitors of phosphodiesterase type-IV
CA2579609A1 (en) 2003-09-10 2005-03-17 Virochem Pharma Inc. Spirohydantoin compounds and methods for the modulation of chemokine receptor activity
ATE380813T1 (de) * 2003-10-03 2007-12-15 Pfizer Imidazopyridinsubstituierte tropanderivate mit ccr5-rezeptorantagonistischer wirkung zur behandlung von hiv und entzündungen
TW200610761A (en) * 2004-04-23 2006-04-01 Astrazeneca Ab Chemical compounds
EP1761542B1 (en) 2004-06-09 2008-01-02 F.Hoffmann-La Roche Ag Octahydropyrrolo[3,4-c]pyrrole derivatives an their use as antiviral agents
WO2006055660A2 (en) * 2004-11-19 2006-05-26 Boehringer Ingelheim International Gmbh Method for treating hiv infection through co-administration of tipranavir and uk-427, 857
WO2006064340A2 (en) * 2004-12-13 2006-06-22 Pfizer Limited Process for the preparation of n-acyl beta-aminoaldehydes
US7665658B2 (en) 2005-06-07 2010-02-23 First Data Corporation Dynamic aggregation of payment transactions
ES2438019T3 (es) 2005-07-22 2014-01-15 Cytodyn, Inc. Procedimientos para reducir la carga viral en pacientes infectados por el VIH-1
BRPI0617720A2 (pt) 2005-10-19 2011-08-02 Hoffmann La Roche compostos inibidores de nnrt de fenil-acetamida, usos dos referidos compostos e composição farmacêutica que os contém
PT2057125E (pt) 2006-08-16 2011-05-31 Hoffmann La Roche Inibidores n?o nucle?sidos de transcriptase inversa
US7932235B2 (en) 2006-11-17 2011-04-26 Concert Pharmaceuticals, Inc. Triazolyl tropane derivatives
JP5415957B2 (ja) 2006-12-13 2014-02-12 エフ．ホフマン−ラ ロシュ アーゲー 非ヌクレオシド逆転写酵素阻害剤としての２−（ピペリジン−４−イル）−４−フェノキシ−又はフェニルアミノ−ピリミジン誘導体
US20080146605A1 (en) * 2006-12-19 2008-06-19 Auspex Pharmaceuticals, Inc. Preparation and utility of ccr5 inhibitors
US20080207659A1 (en) 2007-02-15 2008-08-28 Asit Kumar Chakraborti Inhibitors of phosphodiesterase type 4
WO2008132128A2 (en) * 2007-04-27 2008-11-06 Solvay (Société Anonyme) Synthesis of a pharmaceutically active compound
US20110059154A1 (en) * 2008-02-29 2011-03-10 Strizki Julie M Ccr5 antagonists as prophylactics for preventing hiv infection and methods of inhibiting transmission of same
CN101712679B (zh) * 2008-10-08 2013-04-10 中国科学院上海药物研究所 一种酰胺类化合物、其药物组合物及其制备方法和用途
JP5730871B2 (ja) * 2009-07-24 2015-06-10 グラクソスミスクライン エルエルシー 治療化合物
CN102140104B (zh) * 2010-02-03 2014-11-12 中国科学院上海药物研究所 1-(3-(s)-氨基丙基)-哌啶-4-氨基酰胺类化合物、其药物组合物及其制备方法和用途
MA34215B1 (fr) 2010-04-02 2013-05-02 Phivco 1 Llc Traitement d'association comprenant un antagoniste du récepteur ccr5, un inhibiteur de la protéase du vih-1 et un accélérateur pharmacocinétique
CN103159754A (zh) * 2011-12-19 2013-06-19 中国科学院上海药物研究所 一种氨基丙基取代托烷胺类化合物、其药物组合物及其制备方法和用途
WO2014068265A1 (en) 2012-10-29 2014-05-08 Cipla Limited Antiviral phosphonate analogues and process for preparation thereof
CZ306455B6 (cs) 2013-04-26 2017-02-01 Zentiva, K.S. Nový způsob syntézy Maravirocu
CN103497164B (zh) * 2013-09-23 2015-12-23 西安近代化学研究所 一种蒽衍生物及其制备方法
CN104304248B (zh) * 2014-10-23 2016-08-10 西北农林科技大学 3-芳基丙酸酯类化合物作为制备杀螨药物的应用
CN104402883B (zh) * 2014-10-24 2016-04-27 艾琪康医药科技（上海）有限公司 4，4-二氟金刚烷甲酰胺衍生物、药物组合物及其制备方法和用途
CN104387379B (zh) * 2014-11-26 2017-01-11 扬州氟药科技有限公司 一种二氟亚甲基哌啶甲酰胺衍生物及其制备方法和用途
CN104860946A (zh) * 2015-05-14 2015-08-26 湖北生物医药产业技术研究院有限公司 Ccr5拮抗剂的制备方法
CN107879963A (zh) * 2016-09-29 2018-04-06 中国科学院上海药物研究所 新型手性配体、金属螯合物、多种非天然氨基酸、马拉维诺及其关键中间体的合成方法

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5648511A (en) * 1990-11-19 1997-07-15 G.D. Searle & Co. Method for making intermediates useful in the synthesis of retroviral protease inhibitors
FR2676444B1 (fr) * 1991-05-16 1995-03-10 Sanofi Elf Nouveaux derives d'amino-3 pyridazines actifs sur le systeme nerveux central, procede de preparation et compositions pharmaceutiques en contenant.
GB9310713D0 (en) * 1993-05-24 1993-07-07 Zeneca Ltd Aryl substituted heterocycles
RU2134264C1 (ru) * 1994-04-19 1999-08-10 Нюросерч А/С Производные тропан-2-альдоксима, способ их получения, фармацевтическая композиция и вещества для производства лекарств на их основе и способ лечения растройства или болезни организма
GB9523526D0 (en) * 1995-11-17 1996-01-17 Zeneca Ltd Therapeutic compounds
DE19546462A1 (de) * 1995-12-13 1997-06-19 Bayer Ag Diarylacetylenketone
WO1997024325A1 (en) * 1995-12-28 1997-07-10 Takeda Chemical Industries, Ltd. DIPHENYLMETHANE DERIVATIVES AS MIP-1α/RANTES RECEPTOR ANTAGONISTS
WO1998002151A2 (en) * 1996-07-12 1998-01-22 Leukosite, Inc. Chemokine receptor antagonists and methods of use therefor
US6323206B1 (en) * 1996-07-12 2001-11-27 Millennium Pharmaceuticals, Inc. Chemokine receptor antagonists and methods of use therefor
AU5522498A (en) * 1996-12-13 1998-07-03 Merck & Co., Inc. Substituted aryl piperazines as modulators of chemokine receptor activity
WO1998025604A1 (en) * 1996-12-13 1998-06-18 Merck & Co., Inc. Spiro-substituted azacycles as modulators of chemokine receptor activity
GB9711643D0 (en) 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
EP1003514A4 (en) * 1997-07-25 2000-10-11 Merck & Co Inc CYCLIC AMINE MODULATORS OF CHEMOKIN RECEPTORS
IL125658A0 (en) * 1997-08-18 1999-04-11 Hoffmann La Roche Ccr-3 receptor antagonists
AR013669A1 (es) * 1997-10-07 2001-01-10 Smithkline Beecham Corp Compuestos y metodos
JP2002501052A (ja) * 1998-01-21 2002-01-15 ミレニアム・ファーマシューティカルズ・インコーポレイテッド ケモカイン受容体アンタゴニストおよびその使用方法
EP1013276A1 (en) 1998-12-23 2000-06-28 Pfizer Inc. Aminoazacycloalkanes as CCR5 modulators
US7217714B1 (en) * 1998-12-23 2007-05-15 Agouron Pharmaceuticals, Inc. CCR5 modulators
PE20001420A1 (es) * 1998-12-23 2000-12-18 Pfizer Moduladores de ccr5
ES2215129T3 (es) * 2000-05-26 2004-10-01 Pfizer Inc. Derivados de triazolil tropano como modulares de ccr5.

Also Published As

Publication number Publication date
EP1526134B1 (en) 2008-09-03
BRPI0110955B1 (pt) 2016-06-28
CA2408909A1 (en) 2001-11-29
DE60102233T2 (de) 2005-01-27
UY26727A1 (es) 2001-12-28
CY1108451T1 (el) 2014-04-09
PT1526134E (pt) 2008-10-28
ATE260914T1 (de) 2004-03-15
ME00555B (me) 2011-12-20
NO2010007I2 (no) 2013-09-09
EA005382B1 (ru) 2005-02-24
AU5248201A (en) 2001-12-03
LTPA2008004I1 (lt) 2020-07-27
KR20030004417A (ko) 2003-01-14
CN1437599A (zh) 2003-08-20
EG24137A (en) 2008-08-06
HRP20020938A2 (en) 2005-02-28
KR20050046743A (ko) 2005-05-18
ES2401812T3 (es) 2013-04-24
DK1284974T3 (da) 2004-06-07
JP3693957B2 (ja) 2005-09-14
ATE407134T1 (de) 2008-09-15
NO327892B1 (no) 2009-10-12
BRPI0110955B8 (pt) 2021-05-25
RS50904B (sr) 2010-08-31
NO20025227D0 (no) 2002-10-31
HU225810B1 (en) 2007-10-29
CN1680371A (zh) 2005-10-12
CN100355753C (zh) 2007-12-19
JP2003534343A (ja) 2003-11-18
SI1284974T1 (en) 2004-08-31
AU2001252482B2 (en) 2006-01-19
KR100548854B1 (ko) 2006-02-02
PA8517101A1 (es) 2002-10-24
IL152531A0 (en) 2003-05-29
DE60102233D1 (de) 2004-04-08
EA200401056A1 (ru) 2005-04-28
MA26902A1 (fr) 2004-12-20
PL200551B1 (pl) 2009-01-30
PL359267A1 (en) 2004-08-23
NL300338I1 (nl) 2008-05-01
CZ299102B6 (cs) 2008-04-23
SK286129B6 (sk) 2008-04-07
HUP0302474A3 (en) 2007-05-29
EP1990341B1 (en) 2013-01-23
NO2020019I1 (no) 2020-06-30
EP1526134A3 (en) 2006-11-29
HK1054927A1 (en) 2003-12-19
DE122008000011I1 (de) 2008-06-05
MXPA02011631A (es) 2003-03-27
AR028622A1 (es) 2003-05-14
EA007580B1 (ru) 2006-12-29
KR100523501B1 (ko) 2005-10-25
ES2215129T3 (es) 2004-10-01
ES2311126T3 (es) 2009-02-01
CN1279040C (zh) 2006-10-11
AU2001252482C1 (en) 2001-12-03
NZ521477A (en) 2004-07-30
IS6565A (is) 2002-09-24
SI1526134T1 (sl) 2008-12-31
WO2001090106A3 (en) 2002-03-28
MY156920A (en) 2016-04-15
CA2408909C (en) 2006-06-27
ME00555A (en) 2011-12-20
RS20090438A (en) 2010-05-07
OA12264A (en) 2003-11-10
CY2008006I1 (el) 2009-11-04
HUP0302474A2 (hu) 2003-11-28
BR0110955A (pt) 2003-06-03
LU91417I2 (fr) 2008-04-22
EP1284974B1 (en) 2004-03-03
HRP20020938B1 (en) 2011-05-31
PT1284974E (pt) 2004-06-30
TWI230160B (en) 2005-04-01
RS51436B (en) 2011-04-30
NO2010007I1 (no) 2010-04-08
FR08C0007I2 (fr) 2009-01-15
DK1526134T3 (da) 2008-11-17
AR060159A2 (es) 2008-05-28
WO2001090106A2 (en) 2001-11-29
EP1990341A1 (en) 2008-11-12
LTC1284974I2 (lt) 2020-11-10
PE20011371A1 (es) 2002-01-18
DZ3464A1 (sh) 2001-11-29
CU23288B7 (es) 2008-06-30
AP2002002663A0 (en) 2002-12-31
AP1965A (en) 2009-03-04
JP2005194283A (ja) 2005-07-21
CZ20023806A3 (cs) 2004-01-14
IL152531A (en) 2010-05-17
TR200400541T4 (tr) 2004-04-21
IS2511B (is) 2009-05-15
EE05110B1 (et) 2008-12-15
BG107140A (bg) 2003-05-30
EA200201141A1 (ru) 2003-04-24
EP1526134A2 (en) 2005-04-27
EE200200656A (et) 2004-06-15
HK1090836A1 (en) 2007-01-05
CR10145A (es) 2008-08-19
DE60135685D1 (de) 2008-10-16
GEP20063799B (en) 2006-04-25
BG65966B1 (bg) 2010-07-30
EP1284974A2 (en) 2003-02-26
HK1078573A1 (en) 2006-03-17
SK16432002A3 (sk) 2004-01-08
LU91417I9 (sh) 2019-01-02
MY153023A (en) 2014-12-31
JP4854970B2 (ja) 2012-01-18
NL300338I2 (nl) 2008-06-02
FR08C0007I1 (sh) 2008-04-25
NO20025227L (no) 2002-10-31
TNSN01077A1 (fr) 2005-11-10
CY2008006I2 (el) 2009-11-04
MY131019A (en) 2007-07-31

Similar Documents

Publication Publication Date Title
AP1965A (en) Tropane derivatives useful in therapy.
HRP20090162T1 (en) Quinolinone-carboxamide compounds as 5-ht4 receptor agonists
MXPA03011638A (es) Nuevos derivados de 4-piperazinil indol con afinidad por el receptor 5-ht6.
MXPA05011411A (es) 1,4-diazepinas sustituidas y usos de las mismas.
ATE297910T1 (de) Retinoid x rezeptormodulatoren
BG104372A (en) (benzodioxan, benzofuran or benzopyran) derivatives possessing fundus relaxing properties
PL361361A1 (en) Substituted 1-aminoalkyl-lactams and their use as muscarinic receptor antagonists
MXPA05012247A (es) Derivados de bencimidazol nuevos.
BG104287A (en) Halogensubstituted tetracyclic derivatives of tetrahydrofuran
TW200512201A (en) New heterocyclic amides
HK1081194A1 (en) 6-amino-1h-indazole compounds as phosphodiesterase4 inhibitors, pharmaceutical compositions compris ing the same, and use thereof
YU75101A (sh) Supstituisani biciklični heterocikli, postupak njihove izrade i njihova upotreba kao antigojaznih i hipoholesterolemijskih agenasa
WO2003008412A3 (en) Hetero-bicyclic crf antagonists
NO20062307L (no) Spirofuropyridinarylderivater
MXPA05012360A (es) Derivados de benzotiazol como ligandos receptores de adenosina.
RS20050954A (en) Use of bycyclo/2.2.1/heptane derivatives for the preparation of neuroprotective pharmaceutical compositions
MY128457A (en) 2-aminocarbonyl-9h-purine derivatives
GB0114699D0 (en) Organic compounds